VIP (Vasoactive Intestinal Peptide) vs PT-141 (Bremelanotide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Side-by-Side Comparison
| Aspect | VIP (Vasoactive Intestinal Peptide) | PT-141 (Bremelanotide) |
|---|---|---|
| Mechanism | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. |
| Typical Dosage | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. |
| Administration | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. |
| Side Effects | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. |
| Best For |
Key Differences
Unique to VIP (Vasoactive Intestinal Peptide):
Unique to PT-141 (Bremelanotide):
Detailed Analysis
PT-141 (Bremelanotide) and VIP (Vasoactive Intestinal Peptide) are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose PT-141 (Bremelanotide) for Recovery & Healing. Choose VIP (Vasoactive Intestinal Peptide) for Sleep Quality, Immune Support, Gut Health.